A unique combination to optimize the treatment of CAD

Pr. Alistair Scott Hall PROFESSOR OF CLINICAL CARDIOLOGY UNITED KINGDOM

Professor of Cardiovascular Epidemiology, Leeds Institute of Biomedical and Clinical Science, University of Leeds, Personal Chair from 2001.

Consultant in Cardiology at Leeds Teaching Hospitals NHS Trust.

Lead for Yorkshire & Humber Research Network (Cardiovascular, Renal, Endocrine, Diabetes, Stroke)

Research Summary:

My main interests are focussed on the genetic basis and clinical consequences of premature acute coronary disease.

Having obtained a PhD in Molecular Pharmacology (drug therapy) I then performed a second period of research training in the field of Molecular Biology (genetics).

I have led a series of large clinical studies that include AIREX (Effect of ACE-inhibitor treatment after heart attack); EMMACE-1 (Assessment of patterns and quality of care of UK patients with heart attacks); British Heart Foundation Family Heart Study / MRC ADLIB Project / Wellcome Trust Case Control Study / GRACE Project (Strategic UK projects that address the genetic basis of CAD), EMMACE-2 (Evaluation of impact of new MI definitions and diagnostic tests), SPACE ROCKET Trial (Comparison of simvastatin 40mg and rosuvastatin 10mg in the treatment of acute coronary

syndrome).

I have a growing interest and expertise in the topic of cardiac biomarkers – particularly as they relate to acute coronary syndrome its evaluation and management.

I am fully clinically active (on-call rotas, inpatients, outpatients etc.) and seek to integrate my research with improving routine patient care.

Publications: